Pharmaceutical

Roche eyes alternate mode of administration for Ocrevus in MS

The investigation combines Ocrevus’ subcutaneous formulation with Halozyme’s drug delivery technology.

Jul 13, 2023 - 20:00
Roche eyes alternate mode of administration for Ocrevus in MS
The investigation combines Ocrevus’ subcutaneous formulation with Halozyme’s drug delivery technology.
Read the original article

Tags:

Previous Article

HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology

Next Article

Tenpoint raises funds to develop cell therapies for vision loss

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Xyphos and Kelonia link for immuno-oncology drug development

Xyphos and Kelonia link for immuno-oncology drug develo...

Feb 16, 2024

Inhaled vaccines could stop Covid infections, monkey studies show

Inhaled vaccines could stop Covid infections, monkey st...

Dec 21, 2023

STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves

STAT+: A flurry of research misconduct cases has univer...

Feb 13, 2024